Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adenocarcinoma

Indian Journal of Pathology and Microbiology

Volumn 54, Issue 1, 2011, Pages 32-36

  Jung, Eun Joo ^a   Lee, Ju Han ^b   Min, Byung Wook ^b   Kim, Young Sik ^b   Choi, Jong Sang ^b  

^a Konkuk University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Colorectal cancer; extracellular matrix metalloproteinase inducer; ezrin; fascin; prognosis

Indexed keywords

CD147 ANTIGEN; EZRIN; FASCIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD147; BIOLOGICAL MARKERS; CARRIER PROTEINS; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 79952964018     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.77320     Document Type: Article

References (22)

1. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker? Int J Biochem Cell Biol 2005;7:1787-804. (Pubitemid 40961664)
2. Adams JC. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004;16:590-6. (Pubitemid 39201245)
3. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC. Prognostic significance of fascin expression in advanced colorectal cancer: An immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 2006;6:241.
4. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, et al. Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer 2007;96:1118-26. (Pubitemid 46608324)
5. Tsai WC, Chao YC, Sheu LF, Chang JL, Nieh S, Jin JS. Overexpression of fascin-1 in advanced colorectal adenocarcinoma: Tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2007;23:153-60. (Pubitemid 46868405)
6. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 2004;67:262-70. (Pubitemid 39551711)
7. Yoder BJ, Tso E, Skacel M, Pettay J, Tarr S, Budd T, et al. The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 2005;11:186-92. (Pubitemid 40075794)
8. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, et al. Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 2003;88:537-47. (Pubitemid 36363363)
9. Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000;60:888-91. (Pubitemid 30129521)
10. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005;93:199-204. (Pubitemid 40253722)
11. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001;61:2276-81. (Pubitemid 32692059)
12. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, et al. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006;119:1800-10. (Pubitemid 44356836)
13. Dransfield DT, Bradford AJ, Smith J, Martin M, Roy C, Mangeat PH, et al. Ezrin is a cyclic AMP-dependent protein kinase anchoring protein. EMBO J 1997;16:35-43. (Pubitemid 27032847)
14. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med 2004;10:201-4. (Pubitemid 38581790)
15. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-6. (Pubitemid 38524889)
16. Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis 2007;24:69-78. (Pubitemid 46669242)
17. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Kikuchi A, Yamamoto T, et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett 2002;179:79-86. (Pubitemid 34195656)
18. Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York: American Joint Committee on Cancer, Springer-Verlag; 2010.
19. Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, Laé M, et al. Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 2007;67:6844-53. (Pubitemid 47105531)
20. Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, et al. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 2005;337:355-62. (Pubitemid 41393802)
21. Jin JS, Wu CY, Lin YF, Wang JY, Yu CP, Sheu LF, et al. Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: Tissue microarray analysis of immunostaining score with clinicopathological parameters. Dis Markers 2006;22:309-16.
22. Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, et al. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 2008;39:1737-43.